Statin myopathy: a common dilemma not reflected in clinical trials

Cleve Clin J Med. 2011 Jun;78(6):393-403. doi: 10.3949/ccjm.78a.10073.


Although statins are remarkably effective, they are still underprescribed because of concerns about muscle toxicity. We review the aspects of statin myopathy that are important to the primary care physician and provide a guide for evaluating patients on statins who present with muscle complaints. We outline the differential diagnosis, the risks and benefits of statin therapy in patients with possible toxicity, and the subsequent treatment options.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Diagnosis, Differential
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Muscle Weakness / chemically induced
  • Muscle Weakness / therapy
  • Muscular Diseases / chemically induced*
  • Muscular Diseases / diagnosis
  • Muscular Diseases / therapy
  • Myositis / chemically induced
  • Myositis / diagnosis
  • Myositis / therapy
  • Rhabdomyolysis / chemically induced
  • Rhabdomyolysis / diagnosis
  • Rhabdomyolysis / therapy
  • Risk Factors


  • Hydroxymethylglutaryl-CoA Reductase Inhibitors